Protalix BioTherapeutics, Inc. PLX
2.86 USD +0.29 (+11.28%)
At closeNov 10, 2026, 7:57 PM EST
2.90 +0.04 +1.40%
After hours · Nov 10, 7:57 PM ET
2.45 Day range 2.97
1.65 52-week range 3.19
- YTD
- +58.89%
- 1 year
- +34.27%
News
seekingalpha.com Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript
benzinga.com Protalix BioTherapeutics Q3 2026 Earnings Call Transcript Protalix BioTherapeutics (AMEX:PLX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Protalix BioTherapeutics Affirms FY2026 Sales Guidance of $78.000M-$83.000M vs $71.359M Est Protalix BioTherapeutics (AMEX:PLX) affirms FY2026 sales outlook from $78.000 million-$83.000 million to $78.000 million-$83.000 million vs $71.359 million estimate.
prnewswire.com Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. ET Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million for the same period in 2025 Net income…
globenewswire.com Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200 Boys Town National Research Hospital in Nebraska becomes first activated site in study targeting four rare pediatric lysosomal storage disorders and has now initiated patient screening as Polaryx…
benzinga.com Protalix Biotherapeutics To Present Individual Participant Results From PK And PD Analysis Of Higher-Dose Cohorts Of Its Phase 1 Single Ascending Dose Study Of PRX-115, At ACR Convergence 2026 Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled GoutThe Company previously reported that higher single doses of PRX–115…
prnewswire.com Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout The Company previously reported that higher single doses of PRX–115…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Curis (NASDAQ:CRIS) stock moved upwards by 83.5% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $1.7 million. SCWorx (NASDAQ:WORX) stock increased by…
prnewswire.com Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026 Company to host conference call and webcast at 8:00 a.m. ET CARMIEL, Israel, Nov. 3, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on…
seekingalpha.com Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.
prnewswire.com Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and…
seekingalpha.com Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
benzinga.com Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of…
prnewswire.com Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of…
prnewswire.com Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics…
seekingalpha.com Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript- benzinga.com CORRECTION: Protalix BioTherapeutics Q1 EPS $0.22 Beats $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.06 by 266.67 percent. This is a 540 percent increase over losses of…
benzinga.com Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call 
benzinga.com Earnings Scheduled For May 13, 2026 
prnewswire.com Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen;…
prnewswire.com Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on…
seekingalpha.com Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX's growth thesis centers on Elfabrio's EU approval and…
proactiveinvestors.com Americans are richer in shares, Europeans in bricks – and that matters now American and European households may be growing wealthier at a similar pace, but the composition of that wealth is strikingly different, and those...
proactiveinvestors.com Tesla targets December 2026 for next-generation AI6 chip tape-out Tesla Inc (NASDAQ:TSLA) CEO Elon Musk on Thursday shared an update on the company’s semiconductor plans, indicating that the firm may “tape out” its...
benzinga.com HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
seekingalpha.com Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
proactiveinvestors.com Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its…- benzinga.com Earnings Scheduled For March 18, 2026
- benzinga.com Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi Financial Outlook: Building Durable Growth and Long–Term ValueProtalix enters 2026 with a profitable commercial business through its partnerships and a focused pipeline aligned to areas of high unmet…
- benzinga.com Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.04 by 250 percent. This is a 166.67 percent decrease over earnings…
prnewswire.com Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry…
proactiveinvestors.com Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial...- benzinga.com The European Commission Approves 2mg/kg Every-4-weeks Dosing Regimen For Chiesi And Protalix Biotherapeutics' Elfabrio (Pegunigalsidase Alfa) For Fabry Disease Patients Who Are Stable With An Enzyme Replacement Therapy European Commission approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval frequency from every-two-weeks…
- benzinga.com Chiesi Group's Unit And Protalix BioTherapeutics Say CHMP Of EMA Issues Positive Opinion Recommending Approval Of 2mg/Kg E4W Dosing Regimen For Elfabrio In Fabry Disease Adult Patients Stable With ERT Treatment Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March…
- benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Earnings Scheduled For August 14, 2025 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Earnings Scheduled For May 9, 2025
benzinga.com Earnings Scheduled For March 17, 2025 
benzinga.com Earnings Scheduled For November 14, 2024 - benzinga.com Earnings Scheduled For March 14, 2024 Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 6, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
- benzinga.com Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…
- benzinga.com Earnings Scheduled For August 7, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss at $0.44 per share on revenue of $153.69 million.
- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.